News stories about Merus Labs International (NASDAQ:MSLI) (TSE:MSL) have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Merus Labs International earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave news articles about the company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an impact on the company’s share price in the next few days.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:
- Zacks: Analysts Anticipate Merus Labs International Inc. (MSLI) Will Post Quarterly Sales of $23.32 Million (americanbankingnews.com)
- Merus Labs International Inc : Featured Company News – A Majority of Merus Labs’ Shareholders Approve Acquisition by Dutch Pharma Major Norgine B.V. (4-traders.com)
- $0.01 Earnings Per Share Expected for Merus Labs International Inc. (NASDAQ:MSLI) This Quarter (americanbankingnews.com)
- Merus Labs International Inc. Receives Court Approval in Connection with Proposed Plan of Arrangement with Norgine B.V. (finance.yahoo.com)
Shares of Merus Labs International (NASDAQ MSLI) remained flat at $1.30 on Monday. 1,428 shares of the company were exchanged. The stock has a 50 day moving average price of $1.20 and a 200-day moving average price of $0.94. The company’s market cap is $152.56 million. Merus Labs International has a 1-year low of $0.70 and a 1-year high of $1.33.
Several research analysts recently commented on the company. Zacks Investment Research raised Merus Labs International from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 18th. Canaccord Genuity cut Merus Labs International to a “hold” rating and set a $1.65 price target for the company. in a research report on Thursday, May 11th. Seven equities research analysts have rated the stock with a hold rating, Merus Labs International currently has a consensus rating of “Hold” and a consensus target price of $1.35.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/2722774/merus-labs-international-msli-receiving-somewhat-favorable-news-coverage-report-shows.html.
Merus Labs International Company Profile
Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.
Receive News & Ratings for Merus Labs International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.